Full Press Release Details
Northstrive Biosciences Inc., a Subsidiary
of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity
Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists
NEWPORT BEACH, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE)
-- Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC," "we," or "our"),
announced the submission of a pre-IND meeting request to the FDA. Northstrive anticipates having a Type B pre-IND meeting with the
FDA in the second fiscal quarter of 2025.
Northstrive Biosciences seeks guidance from the
FDA on the acceptability of the nonclinical studies conducted to date and the clinical development plans for EL-22 administered in combination
with GLP-1 receptor agonists being used to treat subjects that are overweight or obese. The FDA is expected to respond to the pre-IND
meeting request within the first fiscal quarter of 2025. If this request is granted, the FDA's response letter will permit a meeting
scheduled for the second fiscal quarter of 2025.
"While we wait for the FDA's response
to our meeting request, we have begun working on the meeting package that will outline our regulatory plans," said Deniel Mero,
Co-founder of Northstrive Biosciences. "Concurrently, we're also arranging our manufacturing, including seeking a cGMP partner,
to lay the groundwork for the EL-22 Investigational New Drug."
EL-22 is a novel, patent-pending engineered probiotic
designed to express myostatin on its surface, targeting the validated myostatin pathway to support muscle health. Preclinical studies,
including a 2022 publication in mdx mice (a model of Duchenne muscular dystrophy), demonstrated significant physiological and functional
improvements. 1 A Phase 1 clinical trial has also been conducted on EL-22 in South Korea, which demonstrated that
EL-22 was generally well-tolerated and safe in healthy volunteers.
Upon regulatory confirmation, Northstrive Biosciences
aims to file the Investigational New Drug application in 2025 and thereafter initiate clinical trials to evaluate the combination of EL-22
with GLP-1 receptor agonists for obesity treatment.
About Northstrive Biosciences
Northstrive Biosciences Inc., a PMGC Holdings
Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Northstrive
Biosciences' lead asset, EL-22, leverages an engineered probiotic approach to address obesity's pressing issue of preserving
muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company
that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently,
our portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. We
are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding
matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential,"
"would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking
statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of
future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations
and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes
that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore,
you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings'
filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section
of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its
other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free
of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as
of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements
to reflect events that occur or circumstances that exist after the date on which they were made.